505
Participants
Start Date
August 31, 2004
Primary Completion Date
September 9, 2015
Study Completion Date
September 9, 2015
Infliximab 5 mg/kg
Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
Infliximab 10 mg/kg
Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
Placebo
Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
Scottsdale
Anaheim
Los Angeles
Oakland
Orange
Denver
Hartford
Orlando
Atlanta
Chicago
Indianapolis
Lexington
Metairie
Laurel
Boston
Plymouth
Rochester
St Louis
Lincoln
Egg Harbor
Great Neck
New Hyde Park
New York
Rochester
Asheville
Chapel Hill
Charlotte
Durham
Winston-Salem
Cincinnati
Cleveland
Oklahoma City
Tulsa
Portland
Beaver Falls
Philadelphia
Pittsburgh
Providence
Memphis
Houston
Burlington
Charlottesville
Seattle
Milwaukee
Federal
Bedford
Box Hill
Garran
Herston
Kogarah
Parkville
Perth
South Brisbane
Innsbruck
Vienna
Antwerp
Brussels
Imeldalaan 9
Leuven
Edmonton
Vancouver
Winnipeg
Hamilton
London
Toronto
Montreal
Québec
Edmonton
Halifax
Pardubice
Prague
Aalborg
Aarhus C
Copenhagen
Hvidovre
Lille
Nancy
Paris
Strasbourg
Toulouse
Berlin
München
Stade
Jerusalem
Kfar Saba
Rehovot
Tel Aviv
Eindhoven
Nijmegen
Rotterdam
Auckland
Christchurch
Basel
Bern
Zurich
Cardiff
Dundee
Glasgow
Harrow
Liverpool
London
Manchester
Collaborators (1)
Janssen Biologics BV
UNKNOWN
Janssen Research & Development, LLC
INDUSTRY